Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
(OSI) Prosidion is developing PSN-9301, a rationally designed dipeptidyl peptidase IV inhibitor acquired from Probiodrug AG, as a potential oral treatment for type 2 diabetes. Phase II clinical trials of PSN-9301 are underway.